[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626659":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":25,"responsibleParty":34,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":64,"whyStopped":25,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":25},{"fullName":5,"class":6},"Jinnah Postgraduate Medical Centre","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crisaborole 2% Cream","EXPERIMENTAL","Participants will apply Crisaborole 2% cream as a thin layer to affected areas twice daily for four weeks.",[13],"Drug: Crisaborole 2% Cream",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Cream","PLACEBO_COMPARATOR","Participants will apply a placebo cream identical in appearance and consistency to Crisaborole 2% cream, twice daily for four weeks.",[19],"Drug: Placebo Cream",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Non-medicated topical cream identical in appearance and packaging to Crisaborole 2% cream, applied twice daily for four weeks.",[15],null,{"type":22,"name":9,"description":9,"armGroupLabels":27,"otherNames":25},[9],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Uroosa Shaikh, FCPS","CONTACT","03366601694","uroosashaikh654@gmail.com",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Uroosa Shailkh","PGR","100626659","phase-4-efficacy-of-crisaborole-2-cream-versus-placebo-in-mild-to-moderate-atopic-eczema-100626659",false,"NCT07438509","Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","Evaluation of the Efficacy of Crisaborole 2% Cream Compared to Placebo in the Management of Mild to Moderate Atopic Eczema","CRISA-AD","Inclusion Criteria:\n\n* Age 12 to 50 years\n* Clinically diagnosed mild to moderate atopic dermatitis (ISGA score 2 or 3)\n* Willing and able to apply topical medication twice daily for four weeks\n* Able to provide written informed consent (parental consent for participants under 18 years)\n\nExclusion Criteria:\n\n* Severe atopic dermatitis (ISGA score 4)\n* Use of systemic corticosteroids, immunosuppressants, or antibiotics within the past two weeks\n* Known hypersensitivity to crisaborole or any component of the formulation\n* Pregnant or lactating women\n* Presence of other significant dermatological conditions that may interfere with evaluation (e.g., psoriasis, scabies)\n* Immunocompromised status (e.g., HIV infection, organ transplant recipient)","ALL","12 Years","50 Years",{"count":50,"type":51},270,"ESTIMATED","INTERVENTIONAL",[54],"PHASE4","This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema. AD is a chronic inflammatory skin condition characterized by itching, redness, and recurrent flares that can significantly impair quality of life.\n\nEligible participants aged 12 to 50 years with mild to moderate AD will be randomly assigned to receive either Crisaborole 2% cream or a placebo cream applied twice daily for four weeks. The primary outcome is treatment success at Day 28, defined using the Investigator's Static Global Assessment (ISGA) as a score of 0 (clear) or 1 (almost clear) with at least a two-grade improvement from baseline.\n\nParticipants will be evaluated at baseline, Day 14, and Day 28. Safety, tolerability, and compliance will also be assessed. The results of this RCT may provide locally relevant evidence to guide the management of mild to moderate AD.",[57,58],"Atopic Dermatitis (AD)","Atopic Eczema",[60,61,62,63],"Mild to Moderate Atopic Dermatitis","Crisaborole","Phosphodiesterase-4 Inhibitor","Topical Therapy","NOT_YET_RECRUITING","2026-03-04",{"date":67,"type":68},"2026-03-06","ACTUAL",{"date":70,"type":51},"2026-03-01",{"date":72,"type":51},"2026-09-01",{"name":5,"class":6}]